Mdxhealth Sa (MDXH)

$3.11

-0.02

(-0.64%)

Market is closed - opens 7 PM, 08 May 2024

Insights on Mdxhealth Sa

  • Increasing Revenue

    Revenue is up for the last 10 quarters, 5.49M → 19.39M (in $), with an average increase of 12.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -10.04M → -10.72M (in $), with an average decrease of 6.7% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 20.7% return, outperforming this stock by 43.0%

Highlights

Market Capitalization
67.4M
Book Value
$0.26
Earnings Per Share (EPS)
-2.1
Wall Street Target Price
8.4
Profit Margin
-61.4%
Operating Margin TTM
-32.51%
Return On Assets TTM
-13.76%
Return On Equity TTM
-521.7%
Revenue TTM
70.2M
Revenue Per Share TTM
2.7
Quarterly Revenue Growth YOY
50.5%
Gross Profit TTM
19.2M
EBITDA
-20.5M
Diluted Eps TTM
-2.1
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.02
EPS Estimate Next Year
-0.65
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.11

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Mdxhealth Sa(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 170.1%

Current $3.11
Target $8.40

Company Financials

FY18Y/Y Change
Revenue
28.3M
↓ 30.04%
Net Income
-32.5M
↑ 164.08%
Net Profit Margin
-114.51%
↓ 84.18%
FY19Y/Y Change
Revenue
11.8M
↓ 58.41%
Net Income
-43.1M
↑ 32.82%
Net Profit Margin
-365.72%
↓ 251.21%
FY20Y/Y Change
Revenue
18.4M
↑ 55.89%
Net Income
-30.0M
↓ 30.38%
Net Profit Margin
-163.33%
↑ 202.39%
FY21Y/Y Change
Revenue
22.2M
↑ 21.05%
Net Income
-30.9M
↑ 2.9%
Net Profit Margin
-138.84%
↑ 24.49%
FY22Y/Y Change
Revenue
37.1M
↑ 66.62%
Net Income
-50.2M
↑ 62.54%
Net Profit Margin
-135.45%
↑ 3.39%
FY23Y/Y Change
Revenue
70.2M
↑ 89.43%
Net Income
-43.1M
↓ 14.12%
Net Profit Margin
-61.4%
↑ 74.05%
Q3 FY22Q/Q Change
Revenue
11.2M
↑ 61.58%
Net Income
-13.5M
↑ 37.3%
Net Profit Margin
-121.05%
↑ 21.41%
Q4 FY22Q/Q Change
Revenue
12.9M
↑ 15.57%
Net Income
-12.4M
↓ 7.88%
Net Profit Margin
-96.49%
↑ 24.56%
Q1 FY23Q/Q Change
Revenue
14.7M
↑ 14.03%
Net Income
-14.7M
↑ 18.19%
Net Profit Margin
-100.01%
↓ 3.52%
Q2 FY23Q/Q Change
Revenue
16.7M
↑ 13.91%
Net Income
-10.6M
↓ 27.72%
Net Profit Margin
-63.46%
↑ 36.55%
Q3 FY23Q/Q Change
Revenue
19.4M
↑ 15.56%
Net Income
-10.0M
↓ 5.47%
Net Profit Margin
-51.91%
↑ 11.55%
Q4 FY23Q/Q Change
Revenue
19.4M
↑ 0.25%
Net Income
-10.7M
↑ 6.72%
Net Profit Margin
-55.26%
↓ 3.35%
FY18Y/Y Change
Total Assets
65.5M
↑ 11.88%
Total Liabilities
13.4M
↓ 10.79%
FY19Y/Y Change
Total Assets
40.6M
↓ 37.95%
Total Liabilities
20.9M
↑ 56.48%
FY20Y/Y Change
Total Assets
31.9M
↓ 21.59%
Total Liabilities
26.0M
↑ 24.41%
FY21Y/Y Change
Total Assets
75.1M
↑ 135.66%
Total Liabilities
28.2M
↑ 8.33%
FY22Y/Y Change
Total Assets
119.1M
↑ 58.69%
Total Liabilities
109.8M
↑ 289.81%
FY23Y/Y Change
Total Assets
129.1M
↑ 8.39%
Total Liabilities
121.9M
↑ 11.02%
Q3 FY22Q/Q Change
Total Assets
122.6M
↑ 109.49%
Total Liabilities
101.1M
↑ 251.66%
Q4 FY22Q/Q Change
Total Assets
119.1M
↓ 2.81%
Total Liabilities
109.8M
↑ 8.63%
Q1 FY23Q/Q Change
Total Assets
150.8M
↑ 26.57%
Total Liabilities
113.1M
↑ 3.03%
Q2 FY23Q/Q Change
Total Assets
142.5M
↓ 5.47%
Total Liabilities
115.9M
↑ 2.43%
Q3 FY23Q/Q Change
Total Assets
135.7M
↓ 4.78%
Total Liabilities
117.9M
↑ 1.73%
Q4 FY23Q/Q Change
Total Assets
129.1M
↓ 4.86%
Total Liabilities
121.9M
↑ 3.42%
FY18Y/Y Change
Operating Cash Flow
-28.5M
↑ 172.12%
Investing Cash Flow
-1.3M
↓ 77.45%
Financing Cash Flow
41.7M
↑ 7172.6%
FY19Y/Y Change
Operating Cash Flow
-22.3M
↓ 21.91%
Investing Cash Flow
-73.0K
↓ 94.57%
Financing Cash Flow
18.0M
↓ 56.89%
FY20Y/Y Change
Operating Cash Flow
-20.2M
↓ 9.17%
Investing Cash Flow
-537.0K
↑ 635.62%
Financing Cash Flow
14.3M
↓ 20.46%
FY21Y/Y Change
Operating Cash Flow
-22.5M
↑ 11.38%
Investing Cash Flow
-1.2M
↑ 124.95%
Financing Cash Flow
66.5M
↑ 365.35%
FY22Y/Y Change
Operating Cash Flow
-34.1M
↑ 51.31%
Investing Cash Flow
-29.2M
↑ 2314.16%
Financing Cash Flow
20.8M
↓ 68.66%
Q3 FY22Q/Q Change
Operating Cash Flow
-9.3M
↑ 44.43%
Investing Cash Flow
-25.6M
-
Financing Cash Flow
22.5M
↓ 2912.77%
Q4 FY22Q/Q Change
Operating Cash Flow
-9.7M
↑ 4.5%
Investing Cash Flow
-2.2M
↓ 91.24%
Financing Cash Flow
-20.0K
↓ 100.09%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.3M
↓ 56.1%
Investing Cash Flow
-1.2M
↓ 44.58%
Financing Cash Flow
38.3M
↓ 191430.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.6M
↑ 31.04%
Investing Cash Flow
-1.6M
↑ 26.73%
Financing Cash Flow
-1.4M
↓ 103.73%

Technicals Summary

Sell

Neutral

Buy

Mdxhealth Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mdxhealth Sa
Mdxhealth Sa
21.48%
-89.97%
-22.25%
-74.08%
-74.08%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-6.03%
13.08%
-0.38%
-7.92%
96.79%
Agilent Technologies Inc.
Agilent Technologies Inc.
-2.21%
29.14%
6.66%
7.13%
84.4%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-1.02%
26.1%
5.58%
23.6%
111.77%
Danaher Corp.
Danaher Corp.
1.85%
26.39%
3.98%
-3.96%
88.86%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.12%
14.71%
20.71%
-1.02%
72.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mdxhealth Sa
Mdxhealth Sa
NA
NA
NA
-1.02
-5.22
-0.14
NA
0.26
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.03
49.03
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
32.89
32.89
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.35
37.35
2.81
21.53
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
45.86
45.86
3.13
7.63
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.18
32.18
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mdxhealth Sa
Mdxhealth Sa
Buy
$67.4M
-74.08%
NA
-61.4%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.1B
96.79%
49.03
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$40.8B
84.4%
32.89
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$220.4B
111.77%
37.35
13.99%
Danaher Corp.
Danaher Corp.
Buy
$185.5B
88.86%
45.86
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.8B
72.0%
32.18
9.06%

Institutional Holdings

  • Alyeska Investment Group, L.P.

    1.02%

Corporate Announcements

  • Mdxhealth Sa Earnings

    Mdxhealth Sa’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Mdxhealth Sa
Employees
0
CEO
Mr. Michael K. McGarrity
Industry
Healthcare

FAQs